Abstract:Background/Objectives: Although the overall survival prognosis of patients in advanced stages of pancreatic ductal adenocarcinoma (PDAC) is poor, typically ranging from days to months from diagnosis, there are rare cases of patients remaining in therapy for longer periods of time. Early estimations of survival prognosis would allow rational decisions on complex therapy interventions, including radical surgery and robust systemic therapy regimens. Understandably, there is great interest in finding prognostic markers that can be used for patient stratification. We determined the role of various KRAS mutations in the prognosis of PDAC patients using biopsy samples and circulating tumor DNA. Methods: A total of 118 patients with PDAC, clinically confirmed by endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNB), were included in the study. DNA was extracted from cytological slides following a standard cytology evaluation to ensure adequacy (viability and quantity) and to mark the tumor cell fraction. Circulating tumor DNA (ctDNA) was extracted from plasma samples of 45 patients in stage IV of the disease. KRAS mutations in exons 12 and 13 were detected by denaturing capillary electrophoresis (DCE), revealing a minute presence of mutation-specific heteroduplexes. Kaplan–Meier survival curves were calculated for individual KRAS mutation types. Results:KRAS mutations were detected in 90% of tissue (106/118) and 44% of plasma (20/45) samples. All mutations were localized at exon 2, codon 12, with G12D (GGT > GAT) being the most frequent at 44% (47/106) and 65% (13/20), followed by other types including G12V (GGT > GTT) at 31% (33/106) and 10% (2/20), G12R (GGT > CGT) at 17% (18/106) and 10% (2/20), G12C (GGT/TGT) at 5% (5/106) and 0% (0/20) and G12S (GGT/AGT) at 1% (1/106) and 5% (1/20) in tissue and plasma samples, respectively. Two patients had two mutations simultaneously (G12V + G12S and G12D + G12S) in both types of samples (2%, 2/106 and 10%, 2/20 in tissue and plasma samples, respectively). The median survival of patients with the G12D mutation in tissues was less than half that of other patients (median survival 101 days, 95% CI: 80–600 vs. 228 days, 95% CI: 184–602), with a statistically significant overall difference in survival (p = 0.0080, log-rank test), and furthermore it was less than that of all combined patients with other mutation types (101 days, 95% CI: 80–600 vs. 210 days, 95% CI: 161–602, p = 0.0166). For plasma samples, the survival of patients with this mutation was six times shorter than that of patients without the G12D mutation (27 days, 95% CI: 8–334 vs. 161 days, 95% CI: 107–536, p = 0.0200). In contrast, patients with detected KRAS G12R in the tissue survived nearly twice as long as other patients in the aggregate (286 days, 95% CI: 70–602 vs. 162 days, 95% CI: 122–600, p = 0.0374) or patients with other KRAS mutations (286 days, 95% CI: 70–602 vs. 137 days, 95% CI: 107–600, p = 0.0257). Conclusions: Differentiation of specific KRAS mutations in EUS-FNB and ctDNA (above all, the crucial G12D and G12R) is feasible in routine management of PDAC patients and imperative for assessment of prognosis.

K-Ras Gene Mutation in the Diagnosis of Ultrasound Guided Fine-Needle Biopsy of Pancreatic Masses

Values of Mutations of K-ras Oncogene at Codon 12 in Detection of Pancreatic Cancer: 15-Year Experience

Detection Of Kras Gene Mutations In Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy For Improving Pancreatic Cancer Diagnosis

Detection of K-ras Gene Mutation at Codon 12 by Pancreatic Duct Brushing for Pancreatic Cancer.

Digital PCR-based cell-free DNA K-Ras mutations analysis and clinical implication in pancreatic cancer.

K-Ras Mutation Detection in Liquid Biopsy and Tumor Tissue As Prognostic Biomarker in Patients with Pancreatic Cancer: a Systematic Review with Meta-Analysis

Differential High-Resolution Melting Analysis for the Detection of K-ras Codons 12 and 13 Mutations in Pancreatic Cancer.

Identification of K-ras Mutations in Pancreatic Juice in the Early Diagnosis of Pancreatic Cancer

The relationship between K-ras gene mutation with clinicopathological and prognosis in gallbladder carcinoma

[K-Ras Gene Mutation in Colorectal Cancer and Its Clinicopathologic Significance].

K-ras Mutational Status Predicts Poor Prognosis in Unresectable Pancreatic Cancer

Detection of K-ras Mutation in Colorectal Cancer and Its Clinicopathological Significance

Unlabeled-probe High-Resolution Melting to Detect KRAS Codon 12 and 13 Mutations in Pancreatic Adenocarcinoma Tissues

Modified PNA-PCR Method

Rapid Detection of K-ras Gene Point Mutation in Pancreatic Adenocarcinoma by Pyrosequencing

Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer

Co-amplification at Lower Denaturation-temperature PCR Combined with Unlabled-probe High-resolution Melting to Detect KRAS Codon 12 and 13 Mutations in Plasma-circulating DNA of Pancreatic Adenocarcinoma Cases

Detection of K-ras gene mutations in bile and bile duct brushings for diagnosis of cholangiocarcinamas

Diagnosis of pancreatic lesions collected by endoscopic ultrasound-guided fine-needle aspiration using next-generation sequencing

Detection of K-ras mutation in advanced colorectal carcinoma by Pyrosequencing

KRAS Mutation Detection with (2S,4r)-4-[18f]fgln for Noninvasive PDAC Diagnosis.